Creative Commons source reading · Alzheimer’s disease and related dementias
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Chad J Swanson; Yong Zhang; Shobha Dhadda; Jinping Wang; June Kaplow; Robert Y K Lai; Lars Lannfelt; Heather Bradley; Martin Rabe; Akihiko Koyama; Larisa Reyderman; Donald A Berry; Scott Berry; Robert Gordon; Lynn D Kramer; Jeffrey L Cummings
Originally published in Alzheimer's research & therapy · 2021-04-17
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clinical trial, utilized a Bayesian design with response-adaptive randomization to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia. Methods BAN2401-G000-201 aimed to establish the effective dose 90% (ED90), defined as the simplest dose that achieves ≥90% of the maximum treatment effect. The primary endpoint was Bayesian analysis of 12-month clinical change on the Alzheimer's Disease Composite Score (ADCOMS) for the ED90 dose, which required an 80% probability of ≥25% clinical reduction in decline versus placebo.
Results
A total of 856 subjects were randomized and 854 were treated (lecanemab, 609; placebo, 245) between December 2012 and November 2017 at 117 sites across North America (the USA and Canada), Europe (France, Germany, Italy, Netherlands, Spain, Sweden, and the UK), and the Asia-Pacific region (Japan and South Korea).
Discussion
This was the first randomized phase 2 clinical trial evaluating subjects with early Alzheimer’s disease receiving treatment with lecanemab, an anti-protofibril antibody that targets soluble aggregated forms of amyloid beta (Aβ), including oligomers and protofibrils. Bayesian response adaptive randomization was employed for efficient subject allocation to the most effective dose(s) in the trial.
Conclusions
This study was designed as an 18-month, proof-of-concept study. The study explored the dose response of lecanemab over three dose levels and two dosing regimens with the objective to establish the most effective (ED90) dose of lecanemab based on ADCOMS. A 12-month primary endpoint was utilized to allow for the opportunity to accelerate the development program, if possible, through the use of a Bayesian adaptive design; however, the study was to complete the blinded 18-month treatment period regardless of the 12-month outcome. The Bayesian design identified 10 mg/kg biweekly as the ED90 dose.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
